AlphAIAlphAI — Financial news for AI agents
investing.comSEP 83 min read$LIFX

Jefferies names five top tech picks after August reporting season

Jefferies selected five tech, media, and telecom stocks post-August 2026 earnings, citing strong balance sheets and pricing power. Picks include Carsales.com (ASX:CAR), REA Group (ASX:REA), Megaport (ASX:MP1), Infratil (NZX:IFT), and Life360 (ASX:360). Price targets and rationales provided for each, with MP1 and 360 noted as oversold. Carsales.com trades at 22x P/E, REA near 2019 P/E lows, and Megaport shows 24% YoY ARR growth.

Original reporting
investing.com
Published Sep 8, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$LIFX
Bullish
medium confidence
Mentioned
$LIFX
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LIFXBullishMed
01

Why it matters

The new buy ratings and price targets provide fresh catalysts that could drive short‑to‑medium term price moves in the listed stocks.

02

Market read

Analyst upgrades can generate immediate buying pressure, especially in niche regional markets.

03

What to watch

Potential headwinds from currency fluctuations and slower global ad spend could temper upside.

Relevance 5/10Novelty 5/10Timing: post‑August 2026 earnings season

Background

Jefferies released its post‑earnings season top‑tech picks for the TMT sector, focusing on balance sheets and pricing power.

Company-level read

Ticker impact

$LIFXBullishMedium confidence
Context

Life360 earned a buy rating with $61 US and $29 AU price targets, driven by advertising and user growth expectations.

Expected impact

moderate upside

Evidence & confidence

Fresh buy rating and targets constitute new actionable data.

Market effects

Sector

Highlights a broader bullish stance on Australian tech and telecom stocks after earnings season.

Regional

May lift sentiment in the ASX tech segment and related NZX renewable assets.

Global

Limited to regional markets; no direct impact on US indices.

Counterpoint

What could challenge this read

Some investors may view the picks as overpriced given elevated valuations and macro‑uncertainty.

Key entities

  • analyst_firm
    Jefferies

    Investment bank issuing the recommendations.

Read at source← All news

Related articles

OCT 28
$CHRSMedAI 8/10

Coherus Oncology, Inc. (CHRS) Reports 89% cORR in 1L ESCC Interim Data

Coherus Oncology (CHRS) reported interim data for tagmokitug plus toripalimab and chemo in 1L ESCC, showing a confirmed ORR of 75% at cutoff, rising to 89% after two later PRs. The company plans to expand enrollment in 1L and 2L ESCC, with safety deemed acceptable. This data is early-to-mid stage validation for Coherus's CCR8 program.

tradingview.com1 min
OCT 28
$MIRAMedAI 8/10

MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes…

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Pot

SEC EDGAR 8-K2 min
OCT 28
$LLYMedAI 8/10

Lilly’s retatrutide beats Ozempic in head-to-head trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase III trial, achieving 19.5-20.9% weight loss vs. Ozempic's 9.4%, and greater A1C reduction. Retatrutide also improved cardiovascular risk factors. Lilly and Novo are competitors in the obesity and type 2 diabetes market, with ongoing legal and market disputes.

finance.yahoo.com2 min
OCT 28
$LLYMedAI 8/10

Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Eli Lilly's experimental drug retatrutide showed greater improvement in type 2 diabetes measures than Novo's Ozempic in a Phase 3 trial, reducing A1C levels by 2.2 points vs. 1.8 for Ozempic. Retatrutide also led to more weight loss and better cardiovascular metrics but had higher side effects. Lilly plans to present detailed data later. Analysts see potential for premium pricing and $15B in 2032 sales if approved.

medcitynews.com2 min